Publication of the Laboratory of Pharmacogenomics: „The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes“

Members of the Laboratory of Pharmacogenomics (K. Šeborová, A. Spálenková, K. Koucká, P. Holý, M. Ehrlichová, P. Souček a R. Václavíková) and colleagues from 3LF UK, 2LF UK, FNKV and Stony Brook University in New York recently published an original research article in International Journal of Molecular Sciences (IF 5.9, Q1 in Biochemistry & Molecular Biology).

In this original work, we summarize the current research results of three selected molecules - ABCC3, TRIP6 and CPS1 and their role in resistance to conventionally used chemotherapy - taxanes in ovarian cancer. Selected molecules were studied at in vitro, in vivo level and in tumor tissue samples from ovarian cancer patients. The study also included monitoring the effect of new experimental taxanes, SB-T taxanes, on these molecules. The most interesting was - CPS1 gene, for which we observed a significant expression downregulation in resistant ovarian cancer lines after treatment of new experimental SB-T taxanes with paclitaxel and in in vivo xenograft model of ovarian cancer. Analysis of patient samples showed a relationship between high CPS1 expression with poor patients´ prognosis. Interesting was also the discovery of loss of ABCC3 expression after taxane treatment in ovarian cancer patients.

Šeborová K.; Spálenková A.; Koucká K.; Holý P.; Ehrlichová M.; Wang C.; Ojima I.; Voleska I.; Daniel P.; Balušíková K.; Jelínek M.; Kovář J.; Rob L.; Hruda M.; Mrhalová M.; Souček P.; Václavíková R.: The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes. Int. J. Mol. Sci.202223(1), 73; doi: 10.3390/ijms23010073.


Mgr. Šeborová Karolína


Charles University
Faculty of Medicine in Pilsen
Biomedical Center

alej Svobody 1655/76
323 00 Plzeň – Severní Předměstí

T: +420 377 593 810
E: This email address is being protected from spambots. You need JavaScript enabled to view it.


Log in to your account or Create an account